Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medmira ( (TSE:MIR) ) has provided an update.
MedMira Inc. has announced an exclusive distribution agreement with Trimedic Inc. to expand its presence in the Canadian market. This partnership follows the Health Canada approval of MedMira’s Multiplo® TP/HIV and Reveal® G4 HIV rapid tests, addressing the urgent need for reliable testing solutions amid rising STI cases in Canada. Trimedic’s established network and expertise in point-of-care diagnostics will support MedMira’s growth, particularly in underserved communities, enhancing access to essential testing devices.
More about Medmira
MedMira Inc. operates in the medical diagnostics industry, focusing on rapid antibody tests for infectious diseases. Their primary products include the Multiplo® TP/HIV and Reveal® G4 HIV rapid antibody tests, which have received Class 4 Medical Device Licenses in Canada. The company is dedicated to product development, regulatory compliance, and manufacturing, aiming to expand its presence in the STI rapid test market.
YTD Price Performance: 4.55%
Average Trading Volume: 96,059
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$87.21M
Learn more about MIR stock on TipRanks’ Stock Analysis page.